Rakhi Khanna, DO
Nephrology · Gurnee, ILNPI 1083689079
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,675 of the $32,255 with a category attached, or 82.7%. AstraZeneca accounts for 77.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $11,794 and has fallen 98.2% since, to $218 in 2025. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $212.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$25K
- Boston Scientific$4K
- Vifor Pharma, Inc.$2K
- Amgen$494
- Mallinckrodt Enterprises LLC$184
- Bayer$145
- plus $1K from 15 others
Across 67 payments — averaging $402.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$17K
- Janssen Research & Development, LLC$10K
What the payments were for
- Speaking & faculty fees$26,67583%
- Travel & lodging$1,4294%
- Food & beverage$4,01712%
- Education$1350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 65 | $25,008 |
| Boston Scientific | 17 | $3,861 |
| Vifor Pharma, Inc. | 8 | $1,557 |
| Amgen(2 entities) | 16 | $494 |
| Mallinckrodt Enterprises LLC | 3 | $184 |
| Bayer | 7 | $145 |
| Bard Peripheral Vascular, Inc. | 1 | $143 |
| Fresenius USA Marketing, Inc. | 6 | $113 |
| Vantive US Healthcare LLC | 1 | $110 |
| Akebia Therapeutics Inc | 6 | $101 |
| Boehringer Ingelheim | 1 | $73 |
| Nxstage Medical, Inc. | 1 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| OPKO Pharmaceuticals, LLC | 4 | $61 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $53 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,255 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 110 | $94,942 |
| LokelmaSodium Zirconium Cyclosilicate | 56 | $45,896 |
| JardianceEmpagliflozin | 21 | $23,732 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $11,535 |
| KerendiaFinerenone | 13 | $9,018 |
| Cinacalcet Hcl | 19 | $6,777 |
| Sevelamer Carbonate | 17 | $5,403 |
| ProcritEpoetin Alfa | 17 | $4,441 |
| Valsartan | 131 | $3,907 |
| Nifedipine ErNifedipine | 25 | $1,177 |
| Chlorthalidone | 30 | $677 |
| Carvedilol | 89 | $578 |
| Furosemide | 63 | $499 |
| Losartan Potassium | 46 | $489 |
| Potassium Citrate ErPotassium Citrate | 12 | $419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $25,008 | $140,838166 claims |
| Boehringer IngelheimJardiance | $73 | $23,73221 claims |
| BayerKerendia | $145 | $9,01813 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $21 | $3,907131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 nephrology providers in Illinois.
Other nephrology in Gurnee
- Omaima DeganiGurnee$184K
- Leon SujataGurnee$20K
- Myles WolfChicago$2.1M
- Mohammed AhmedBolingbrook$1.1M
- Anis RaufHinsdale$453K
- Juan LermaEvergreen Park$351K
- Stuart SpragueEvanston$337K
- Suneel UdaniHinsdale$336K
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.